Oral Cancer Treatment Market 2023 Top Players - Qilu Pharmaceutical Co, Eli Lilly and Co, Merck & Co, Novartis AG, Pfizer Inc and More

The Global Oral Cancer Treatment Market is expected to grow at an approximate CAGR of 7.1% during the forecast period.

Oral cancer or mouth cancer cab be referred to as the cancer of tongue, gums, throat, and others. Squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinomas, and lymphomas are some of the common types of the oral cancer. Increasing prevalence of the oral cancer is the major driver for market growth during the forecast period. In 2017, according to the Oral Cancer Foundation, 49,750 Americans are estimated to be diagnosed with the oral oropharyngeal cancer.

Moreover, it is estimated 9,750 deaths will be accounted for the same. Also, the rising per capita healthcare expenditures followed by growing awareness about oral diseases fuels the market growth. In 2015, according to the Centres for Disease Control and Prevention, in the U.S., the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. However, risks for recurrence of cancer and high cost of treatment may restrain the market growth. According to the Dharamshila Hospital, New Delhi, India, in 2015, the cost of the treatment of the oral cancers can range from USD 2,995 to USD 14,979.

Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/1820 .

Key players for global oral cancer treatment market

The key players for the global oral cancer treatment market are Bristol-Myers Squibb Company (U.S.) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Merck & Co. Inc. (U.S.), Novartis AG (Europe), Pfizer Inc. (U.S.), and others.

Segmentation:

The global oral cancer treatment market is segmented on the basis of type, treatment, and end users.

On the basis of type, the market is segmented into squamous cell carcinoma, verrucous carcinoma, minor salivary gland carcinomas, lymphomas, and others.

On the basis of treatment, the market is segmented into surgery, radiotherapy, chemotherapy, and photodynamic therapy (PDT), and others. The surgery segment is sub segmented into tumor resection, glossectomy, laryngectomy, mohs micrographic surgery, and others. The chemotherapy segment is sub segmented into cisplatin, carboplatin, 5-fluorouracil (5-FU), and others.

On the basis of end users, the market is segmented into hospitals & clinics, research organization, academic institutes, and others.

Get Attractive Discount on This Report @ https://www.marketresearchfuture.com/check-discount/1820 .

Brief TOC

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4 Market Dynamics

…TOC Continued

Inquire about This Report @ https://www.marketresearchfuture.com/enquiry/1820 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.